Lilly’s offering is expected to surpass Novo’s Wegovy in the space, and, according to a report this week from GlobalData, it ...

The emergence of adaptive cardiac devices, especially those that utilise AI, is propelling the wider industry shift towards ...

The surge in tunnelling and anchoring machinery patents is driven by the need for technological innovation to improve mining processes.

Operational risks are also reduced due to a lesser need for human intervention in hazardous environments, which is a very ...

According to key opinion leaders, positive SURMOUNT-5 results, alongside Lilly’s business strategy, means Zepbound is set to ...

The growing adoption of smart home technology is enabling consumers to both spot damage early and reduce its impact by ...

In a release sent to Rigzone recently, GlobalData said the oil and gas industry has seen a dip in active jobs in 2024 but ...

KOLs interviewed by GlobalData stressed the lack of biologic therapies specifically targeting T2-low asthma.

Virtual reality primarily has applications around training across the oil and gas value chain,' GlobalData said.

AI-driven adaptive cardiac devices are revolutionizing heart disease treatment by enabling real-time monitoring and dynamic ...

Eli Lilly's Zepbound is challenging Wegovy in the obesity market, while U.S. health care costs are set to rise 9% in 2025, driven by specialty drugs and inflation.

New Delhi: Eli Lilly’s Zepbound drug holds potential to dominate the global obesity market due to its superior efficacy and ...